Control of Degrees of Freedom Post-stroke for the Recovery of the Upper Limb (DoF_UL_S)

April 24, 2024 updated by: Pablo Burgos, University of Chile

Effects of Control of Joint Degrees of Freedom in the Early Rehabilitation Post-stroke for the Recovery of Normal Movement (Non-compensatory) of the Upper Limb

The study's methodology will be a single-blind, multicenter, parallel-group randomized controlled trial (RCT). The sample consists of stroke patients (supratentorial ischemic and hemorrhagic stroke of anterior territory) between 18 and 80 years of age, separated into 2 groups of 20 participants. The experimental group called "controlled DoF", the control group 1 called "non controlled DoF". The "controlled DoF" group will use an exoskeleton that will restrict the movement of the trunk and upper limb to release only the joint to work in the plane of interest. The "non-controlled DoF" group will receive the same therapy time as the previous group but without any restriction of joint movements. The training will be functional with multiarticular and combined planes tasks. All groups receive the conventional rehabilitation of the health center (ideally 45 minutes 1 per day). Using motion sensors, clinical scales, and electroencephalography (EEG), the data will be obtained pre-intervention, post-intervention, and in a follow-up at 3 and 6 months.

Study Overview

Detailed Description

This proposal seeks to demonstrate if the control of joint degrees of freedom (DoF) of the trunk and upper limb is determinant during the early rehabilitation phase post-stroke (here from day 1 to day 28 or first month) for the recovery of upper limb movements without compensations and the normal brain control (true recovery).

The study's methodology will be a single-blind, multicenter, parallel-group randomized controlled trial (RCT). The sample consists of stroke patients (supratentorial ischemic and hemorrhagic stroke of anterior territory) between 18 and 80 years of age, separated into 2 groups of 20 participants. The experimental group called "controlled DoF", the control group 1 called "non controlled DoF". The "controlled DoF" group will receive for the initial 2 weeks, 2 hours of therapy, 5 times a week (2 sessions of 1 hour per day, 5 days) and the next 2 weeks, 2 hours of therapy, 3 times a week(2 sessions of 1 hour of therapy, 3 days), using an exoskeleton that will restrict the movement of the trunk and upper limb to release only the joint to work in the plane of interest. The training will be selective in an articulation plane with the biofeedback of active movements (or active-assisted) employing a video game controlled by an external movement sensor installed in the segment of interest. The "non-controlled DoF" group will receive the same therapy time as the previous group but without any restriction of joint movements. The training will be functional with multiarticular and combined planes tasks. All groups receive the conventional rehabilitation of the health center (ideally 45 minutes 1 per day). Using motion sensors, clinical scales, and electroencephalography (EEG), the data will be obtained pre-intervention, post-intervention, and in a follow-up at 3 and 6 months.

The expected results would show more functional improvements with less compensatory kinematics for therapy that control DoF than for the therapy without control of the DoF or for conventional therapy in acute post-stroke patients. About this result, the EEG connectivity analysis would show a lower interhemispheric inhibition of the motor areas and a greater frontal-parietal flow during reaching and manipulation tasks in the group with DoF control.

Study Type

Interventional

Enrollment (Actual)

45

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Santiago, Chile, 8320000
        • Hospital Clínico Universidad de Chile

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • (1) Clinical diagnosis of supratentorial ischemic stroke.
  • (2) Time of onset <72 hours.
  • (3) With alterations of the active voluntary movement of UL.
  • (4) At least 3/8 DoF of the UE with MRC force scale of 3 or less.

Exclusion Criteria:

  • (1) Cognitive impairment that prevents signing informed consent, following instructions and understanding procedures. (MoCA ≥ 18).
  • (2) Musculoskeletal pathologies that prevent activities without pain or with limited ranges for the scope.
  • (3) Severe visual impairment that does not allow the activities associated with the task.
  • (4) Cerebellar o brainstem stroke.
  • (5) Previous stroke leaving upper limb impairment.
  • (6) Bilateral sensorimotor alterations.
  • (7) Do not present alterations in functional clinical tests.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Controlled DoF
The treatment that this gruop will receive consist in a training with the exoskeleton that will restrict the DoF of the arm and trunk
The intervention is based in the training of a single DoF of the upper extremity with restriction of the rest DoF of the arm and trunk that aren't being trained being restrained by an exoskeleton
Active Comparator: Non controlled DoF
The treatment that this gruop will receive consist in a training with out the exoskeleton and without restriction of the DoF
The intrevention is based in the training of the upper extremity movements without the restriction of DoF

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Normal movements Outcome. Kinematics of grasping and reaching 1
Time Frame: At week 1
Joint angles of the upper extremity in a water glass test
At week 1
Normal movements Outcome. Kinematics of grasping and reaching 2
Time Frame: At week 5
Joint angles of the upper extremity in a water glass test
At week 5
Normal movements Outcome. Kinematics of grasping and reaching 3
Time Frame: At week 12
Joint angles of the upper extremity in a water glass test
At week 12
Normal movements Outcome. Kinematics of grasping and reaching 4
Time Frame: At week 24
Joint angles of the upper extremity in a glass test
At week 24
Functioning Outcome 1
Time Frame: At week 1
Scale scores of Fugl Meyer Upper Limb test
At week 1
Functioning Outcome 2
Time Frame: At week 5
Scale scores of Fugl Meyer Upper Limb test
At week 5
Functioning Outcome 3
Time Frame: At week 12
Scale scores of Fugl Meyer Upper Limb test
At week 12
Functioning Outcome 4
Time Frame: At week 24
Scale scores of Fugl Meyer Upper Limb test
At week 24
Functioning Outcome - function of the arm1
Time Frame: At week 1
Scale scores of ARAT (Action Research Arm Test)
At week 1
Functioning Outcome - function of the arm 2
Time Frame: At week 5
Scale scores of ARAT (Action Research Arm Test)
At week 5
Functioning Outcome - function of the arm 3
Time Frame: At week 12
Scale scores of ARAT (Action Research Arm Test)
At week 12
Functioning Outcome - function of the arm 4
Time Frame: At week 24
Scale scores of ARAT (Action Research Arm Test)
At week 24
Functioning Outcome - daily life activities 1
Time Frame: At week 1
Scale scores of Barthel Index (independence in daily life activities)
At week 1
Functioning Outcome - daily life activities 2
Time Frame: At week 5
Scale scores of Barthel Index (independence in daily life activities)
At week 5
Functioning Outcome - daily life activities 3
Time Frame: At week 12
Scale scores of Barthel Index (independence in daily life activities)
At week 12
Functioning Outcome - daily life activities 4
Time Frame: At week 24
Scale scores of Barthel Index (independence in daily life activities)
At week 24
Functioning Outcome - quality of life 1
Time Frame: At week 1
Scale scores of EQ-5D (quality of life test)
At week 1
Functioning Outcome - quality of life 2
Time Frame: At week 5
Scale scores of EQ-5D (quality of life test)
At week 5
Functioning Outcome - quality of life 3
Time Frame: At week 12
Scale scores of EQ-5D (quality of life test)
At week 12
Functioning Outcome - quality of life 4
Time Frame: At week 24
Scale scores of EQ-5D (quality of life test)
At week 24
Connectivity Outcome 1
Time Frame: At week 1
Interhermispheric coherence of beta bands in the EEG.
At week 1
Connectivity Outcome 2
Time Frame: At week 5
Interhermispheric coherence of beta bands in the EEG.
At week 5
Connectivity Outcome 3
Time Frame: At week 12
Interhermispheric coherence of beta bands in the EEG.
At week 12
Connectivity Outcome 4
Time Frame: At week 24
Interhermispheric coherence of beta bands in the EEG.
At week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Pedro Maldonado, Doctor, University of Chile

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2021

Primary Completion (Actual)

April 19, 2024

Study Completion (Actual)

April 19, 2024

Study Registration Dates

First Submitted

April 26, 2021

First Submitted That Met QC Criteria

May 7, 2022

First Posted (Actual)

May 12, 2022

Study Record Updates

Last Update Posted (Actual)

April 26, 2024

Last Update Submitted That Met QC Criteria

April 24, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • hcuch_038
  • 11181337 (Other Grant/Funding Number: Fondecyt ANID)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Training with restriction of the DoF

Subscribe